PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Intestinal Research10.5217/ir.2018.16.3.4942018163494Effect of elemental diet combined with infliximab dose escalation in patients with Crohn's disease with loss of response to infliximab: CERISIER trialTadakazu Hisamatsu, Reiko Kunisaki, Shiro Nakamura, Tomoyuki Tsujikawa, Fumihito Hirai, Hiroshi Nakase, Kenji Watanabe, Kaoru Yokoyama, Masakazu Nagahori, Takanori Kanai, Makoto Naganuma, Hirofumi Michimae, Akira Andoh, Akihiro Yamada, Tadashi Yokoyama, Noriko Kamata, Shinji Tanaka, Yasuo Suzuki, Toshifumi Hibi, Mamoru Watanabe, https://synapse.koreamed.org/pdf/10.5217/ir.2018.16.3.494, https://synapse.koreamed.org/DOIx.php?id=10.5217/ir.2018.16.3.494, http://www.irjournal.org/upload/pdf/ir-16-494.pdf
Alimentary Pharmacology & Therapeutics10.1111/j.1365-2036.2007.03548.x20072611-121509-1520Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn’s disease: a cost-effectiveness analysisG. G. KAPLAN, C. HUR, J. KORZENIK, B. E. SANDShttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1365-2036.2007.03548.x, http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2036.2007.03548.x/fullpdf
Journal of Crohn's and Colitis10.1093/ecco-jcc/jjab232.567202216Supplement_1i422-i423P440 Loss of response and dose escalation of infliximab and adalimumab in Ulcerative Colitis patients: A Systematic Review and Meta-analysisE Savelkoul, P Thomas, L Derikx, N Den Broeder, T Römkens, F Hoentjenhttps://academic.oup.com/ecco-jcc/article-pdf/16/Supplement_1/i422/42251450/jjab232.567.pdf, https://academic.oup.com/ecco-jcc/article-pdf/16/Supplement_1/i422/42251450/jjab232.567.pdf
Gastroenterology10.1016/s0016-5085(10)63226-x20101385S-701-S-702W1335 Previous Non-Response to Infliximab Predicts Early Dose-Escalation in Adalimumab Treated Crohn's Disease PatientsEvelien Bultman, Rachel L. West, Astrid van Liere-Baron, Ernst J. Kuipers, Zuzana Zelinkova, Janneke V. Woudehttps://api.elsevier.com/content/article/PII:S001650851063226X?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S001650851063226X?httpAccept=text/plain
Gastroenterology10.1016/s0016-5085(16)31462-720161504S421Sa1974 Rational Infliximab De-Escalation in Crohn's Patients in Remission Using Infliximab LevelsJessica R. Allegretti, Madeline Carrellas, Matthew Hamilton, Sonia Friedman, Joshua R. Korzenikhttps://api.elsevier.com/content/article/PII:S0016508516314627?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0016508516314627?httpAccept=text/plain
The American Journal of Gastroenterology10.1038/ajg.2008.8820091043760-767Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A ReviewJavier P Gisbert, Julián Panéshttp://www.nature.com/articles/ajg200888.pdf, http://www.nature.com/articles/ajg200888, http://www.nature.com/articles/ajg200888.pdf
Gastroenterology10.1016/s0016-5085(10)63161-720101385S-687-S-688W1270 Discriminating Between Response Types in Infliximab-Treated Patients With Crohn's Disease: Sensitivity and Specificity of Combined Assessment of Infliximab Trough Levels and Anti-Drug AntibodiesCasper Steenholdt, Ole O. Thomsen, Jorn Brynskov, Klaus Bendtzen, Mark A. Ainsworthhttps://api.elsevier.com/content/article/PII:S0016508510631617?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0016508510631617?httpAccept=text/plain
Gastroenterology10.1016/s0016-5085(03)81925-x20031244A380Effect of antibodies to infliximab on infusion reaction and clinical response in patients with fistulizing Crohn's disease receiving maintenance treatment with infliximabCarrie Wagner, Joyce Ford, Paul Marsters, Suzanne Travers, Weihang Bao, Sander J. Van Deveneterhttps://api.elsevier.com/content/article/PII:S001650850381925X?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S001650850381925X?httpAccept=text/plain
Gastroenterology10.1016/s0016-5085(13)61592-920131445S-433Su1225 Concomitant Elemental Diet Therapy Is Effective in Sustaining Infliximab Scheduled Maintenance Therapy in Patients With Crohn's Disease to Prevent Loss of ResponseNoriko Kamata, Kenji Watanabe, Takuya Tsukahara, Yoshie Hagihara, Kenichi Morimoto, Atsushi Noguchi, Takako Miyazaki, Mitsue Sogawa, Hirokazu Yamagami, Tetsuya Tanigawa, Masatsugu Shiba, Toshio Watanabe, Kazunari Tominaga, Yasuhiro Fujiwara, Tetsuo Arakawahttps://api.elsevier.com/content/article/PII:S0016508513615929?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0016508513615929?httpAccept=text/plain
Nature Clinical Practice Gastroenterology & Hepatology10.1038/ncpgasthep09362007411588-589Infliximab dose intensification in patients with Crohn's diseasehttp://www.nature.com/articles/ncpgasthep0936.pdf, http://www.nature.com/articles/ncpgasthep0936, http://www.nature.com/articles/ncpgasthep0936.pdf